KD Logo

Examining the Potential Price Growth of Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc’s recently made public that its CFO and CBO Henderson Molly unloaded Company’s shares for reported $38128.0 on Apr 08 ’24. In the deal valued at $11.10 per share,3,435 shares were sold. As a result of this transaction, Henderson Molly now holds 95,263 shares worth roughly $1.0 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Curran Terrie sold 16,851 shares, generating $153,513 in total proceeds. Upon selling the shares at $9.11, the President and Chief Executive now owns 410,784 shares.

Before that, TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares. Phathom Pharmaceuticals Inc shares valued at $29,999,994 were divested by the 10% Owner at a price of $8.10 per share. As a result of the transaction, TAKEDA PHARMACEUTICAL CO LTD now holds 3,755,583 shares, worth roughly $39.58 million.

Stifel initiated its Phathom Pharmaceuticals Inc [PHAT] rating to a Buy in a research note published on May 03, 2024; the price target was $24. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering PHAT with “Buy” recommendation on August 09, 2023. Evercore ISI revised its rating on May 11, 2023. It rated PHAT as “an Outperform” which previously was an “an In-line”.

Price Performance Review of PHAT

On Friday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock fall -1.40% to $10.54. Over the last five days, the stock has gained 10.66%. Phathom Pharmaceuticals Inc shares have risen nearly 15.44% since the year began. Nevertheless, the stocks have fallen -20.57% over the past one year. While a 52-week high of $17.02 was reached on 04/09/24, a 52-week low of $6.07 was recorded on 02/13/24. SMA at 50 days reached $9.80, while 200 days put it at $9.82. A total of 0.53 million shares were traded, compared to the trading of 0.33 million shares in the previous session.

Levels Of Support And Resistance For PHAT Stock

The 24-hour chart illustrates a support level at 10.27, which if violated will result in even more drops to 10.00. On the upside, there is a resistance level at 10.79. A further resistance level may holdings at 11.05. The Relative Strength Index (RSI) on the 14-day chart is 57.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.50, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 30.70%. Stochastics %K at 69.68% indicates the stock is a holding.

The most recent change occurred on March 13, 2023 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.

Most Popular